Multiply Labs mentioned its modular strategy to cell remedy automation reduces manufacturing bottlenecks. | Supply: Multiply Labs
Multiply Labs Inc. at present introduced an settlement with AstraZeneca to guage the potential for making use of good manufacturing apply, or GMP-ready, robotic programs to commercial-scale cell remedy manufacturing. The collaboration will concentrate on automation of industry-standard devices utilized in cell remedy manufacturing utilizing Multiply Labs’ robotic biomanufacturing system.
The objective is to allow scalable, high-throughput manufacturing whereas sustaining the rigorous high quality and regulatory requirements required for scientific and business use.
“Cell therapies are among the many most promising, but advanced medicines being developed at present,” mentioned Fred Parietti, Ph.D., CEO of Multiply Labs. “Our mission is to make these therapies extra broadly accessible by rising manufacturing effectivity and scale.”
“This settlement with AstraZeneca permits us to guage our multi-arm robotic clusters in a setting the place we will mix among the world’s finest scientific and scientific experience with our robotic platform to construct the following technology of high-throughput, GMP-ready cell remedy manufacturing,” he added.
4-armed robotic maximizes pharmaceutical manufacturing
Based in 2016, Multiply Labs supplies automation to the pharmaceutical {industry}. It develops cloud-controlled robotics for the manufacturing of superior therapies at scale.
The San Francisco-based firm‘s latest programs use 4 robotic arms working in parallel to run a broad vary of cell remedy manufacturing devices already in use by the {industry}. It mentioned this structure minimizes the necessity for course of modifications whereas maximizing output in present amenities, concentrating on increased productiveness.
Multiply Labs claimed that its clients embrace among the largest pharmaceutical producers on this planet. The corporate asserted that its experience is on the intersection of robotics and biopharma – its group contains mechanical engineers, electrical engineers, laptop scientists, software program engineers, and pharmaceutical scientists.
Multiply Labs builds associate community
This isn’t the primary partnership Multiply Labs has made in its efforts to automate cell remedy manufacturing. In September, it partnered with Thermo Fisher Scientific. The collaboration is specializing in integrating robots with Thermo Fisher’s automated Gibco CTS DynaCellect Magnetic Separation System.
The Gibco CTS DynaCellect System is a closed, automated isolation, activation, and bead-removal system for cell remedy growth and manufacturing. Along with fit-for-purpose consumables, it presents excessive cell purity, restoration, and viability.
By combining the Gibco CTS DynaCellect System with Multiply Labs’ robotic automation experience, the companions mentioned they hope to speed up crucial steps in cell remedy manufacturing by decreasing handbook intervention and enhancing course of consistency.
In June, Multiply Labs introduced a pilot collaboration with Kyverna Therapeutics, a clinical-stage biopharmaceutical firm centered on creating cell therapies for sufferers with autoimmune ailments. Kyverna deliberate to guage the automation of its cell remedy manufacturing processes utilizing Multiply Labs’ robotic programs for KYV-102.
